A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF-04449913) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

被引：19
|
作者：
Cortes, Jorge E. [1 ]
Heidel, Florian H. [2 ,3 ]
Heuser, Michael [4 ]
Fiedler, Walter [5 ,6 ]
Smith, B. Douglas [7 ]
Robak, Tadeusz [8 ,9 ]
Fernandez, Pau Montesinos [10 ]
Ma, Weidong Wendy [11 ]
Shaik, M. Naveed [12 ]
Zeremski, Mirjana [12 ]
O'Connell, Ashleigh [13 ]
Chan, Geoffrey [13 ]
机构：
[1] Univ Texas M Anderson Canc Ctr, Houston, TX USA
[2] Otto Guericke Univ Med Ctr, Dept Hematol, Ctr Internal Med, Magdeburg, Germany
[3] Otto Guericke Univ Med Ctr, Dept Oncol, Ctr Internal Med, Magdeburg, Germany
[4] Hannover Med Sch, Hannover, Germany
[5] Univ Med Ctr Eppendorf, Hubertus Wald Univ Canc Ctr, Dept Oncol, Hamburg, Germany
[6] Univ Med Ctr Eppendorf, Hubertus Wald Univ Canc Ctr, Dept Hematol, Hamburg, Germany
[7] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[8] Med Univ Lodz, Dept Hematol, Lodz, Poland
[9] Copernicus Mem Hosp, Lodz, Poland
[10] Hosp Univ Fe, Valencia, Spain
[11] Pfizer Oncol, New York, NY USA
[12] Pfizer Oncol, La Jolla, CA USA
[13] Pfizer Oncol, Collegeville, PA USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.99.99
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
99
引用
收藏
页数：5
相关论文
共 50 条
  • [41] A Comparison of Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Treated On versus Off Study
    Percival, Mary-Elizabeth
    Buckley, Sarah
    Othus, Megan
    Halpern, Anna
    Huebner, Emily
    Becker, Pamela
    Shaw, Carole
    Shadman, Mazyar
    Walter, Roland
    Estey, Elihu
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S281 - S281
  • [42] High dose ARA-C as consolidation therapy for patients with core binding factor acute myeloid leukemia.
    Ferrara, F
    Copia, C
    Palmieri, S
    Annunziata, M
    Pollio, F
    Mele, G
    Schiavone, EM
    BLOOD, 2000, 96 (11) : 326A - 326A
  • [43] A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
    Sekeres, Mikkael A.
    Schuster, Michael W.
    Joris, Magalie
    Krauter, Jurgen
    Maertens, Johan A.
    Gyan, Emmanuel
    Kovacsovics, Tibor
    Verma, Amit
    Vyas, Paresh
    Wang, Eunice S.
    Ma, Weidong Wendy
    Zeremski, Mirjana
    Kudla, Arthur
    Chan, Geoffrey
    Zeidan, Amer M.
    BLOOD, 2019, 134
  • [44] Clofarabine is active in combination with cytarabine (ara-C) in adult patients (pts) in first relapsed and primary refractory acute leukemia and high-risk myelodysplastic syndrome (MDS).
    Faderl, S
    Gandhi, V
    Garcia-Manero, G
    Thomas, DA
    Cortes, JE
    O'Brien, S
    Estey, E
    Craig, A
    Weiss, J
    Keating, M
    Verstovsek, S
    Giles, FJ
    Kwari, M
    Plunkett, W
    Kantarjian, HM
    BLOOD, 2003, 102 (11) : 615A - 615A
  • [45] Results of Phase 2 Randomized Study of Low-Dose Decitabine With or Without Valproic Acid in Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia
    Issa, Jean-Pierre
    Garcia-Manero, Guillermo
    Huang, Xuelin
    Cortes, Jorge
    Ravandi, Farhad
    Jabbour, Elias
    Borthakur, Gautam
    Brandt, Mark
    Pierce, Sherry
    Kantarjian, Hagop M.
    CANCER, 2015, 121 (04) : 556 - 561
  • [46] SEQUENTIAL HIGH-DOSE ARA-C AND ASPARAGINASE IN THE THERAPY OF PREVIOUSLY TREATED AND UNTREATED PATIENTS WITH ACUTE-LEUKEMIA
    CAPIZZI, RL
    POWELL, BL
    COOPER, MR
    STUART, JJ
    MUSS, HB
    RICHARDS, F
    JACKSON, DV
    WHITE, DR
    SPURR, CL
    ZEKAN, PJ
    CRUZ, JM
    CRAIG, JB
    SEMINARS IN ONCOLOGY, 1985, 12 (02) : 105 - 113
  • [47] GM-CSF priming with successive concomitant therapy with low dose ARA-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome.
    Rossi, HA
    O'Donnell, J
    Sarcinelli, F
    Stewart, FM
    Quesenberry, PJ
    Becker, PS
    BLOOD, 2000, 96 (11) : 326A - 327A
  • [48] A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
    Mattison, Ryan
    Jumonville, Alcee
    Flynn, Patrick James
    Moreno-Aspitia, Alvaro
    Erlichman, Charles
    LaPlant, Betsy
    Juckett, Mark B.
    LEUKEMIA & LYMPHOMA, 2015, 56 (07) : 2061 - 2066
  • [49] Covariate Adjusted Indirect Treatment Comparison (ITC) of Glasdegib Plus Low Dose Ara-C Versus a Hypomethylating Agent for Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy
    Tremblay, Gabriel
    Arondekar, Bhakti
    Chan, Geoffrey
    Shor, Anastasiya
    Forsythe, Anna
    Yun, Su
    BLOOD, 2017, 130
  • [50] Low-Dose Cytarabine With or Without Glasdegib in Newly Diagnosed Patients with Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial
    Papayannidis, Cristina
    Smith, B. Douglas
    Heuser, Michael
    Montesinos, Pau
    Sekeres, Mikkael A.
    Oriol, Albert
    Schiller, Gary
    Candoni, Anna
    Jamieson, Catriona
    Hoang, Caroline J.
    Ma, Weidong Wendy
    Zeremski, Mirjana
    O'Connell, Ashleigh
    Chan, Geoffrey
    Cortes, Jorge E.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S228 - S229
12345